The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience

AimsThe rechargeable Axonics (R) r-SNM System is currently approved and available in Europe and Canada, with US FDA approval pending. This article provides a review of the system along with technique and technical considerations for its implantation based on my clinical experience with the new Axonics r-SNM System. MethodsThe description of the surgical technique and technological considerations for the Axonics r-SNM System is based my clinical experience of 11 cases performed at UHN Toronto Western Hospital. ResultsWhile the Axonics system is intended to provide similar therapy to the existing SNM system, the Axonics system has several new technological advances. Understanding these differences and optimizing surgical technique is anticipated to improve outcomes and patient experience. ConclusionsOverall the Axonics r-SNM System and implant procedure requires minimal learning curve for experienced SNM implanters and provides several enhanced features for physicians and patients. Further experience by others may elucidate other nuances important to the implantation of this novel SNM system.